Does LEUPROLIDE Cause Hormone-refractory prostate cancer? 180 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 180 reports of Hormone-refractory prostate cancer have been filed in association with LEUPROLIDE (Fensolvi). This represents 0.3% of all adverse event reports for LEUPROLIDE.
180
Reports of Hormone-refractory prostate cancer with LEUPROLIDE
0.3%
of all LEUPROLIDE reports
30
Deaths
19
Hospitalizations
How Dangerous Is Hormone-refractory prostate cancer From LEUPROLIDE?
Of the 180 reports, 30 (16.7%) resulted in death, 19 (10.6%) required hospitalization, and 1 (0.6%) were considered life-threatening.
Is Hormone-refractory prostate cancer Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LEUPROLIDE. However, 180 reports have been filed with the FAERS database.
What Other Side Effects Does LEUPROLIDE Cause?
Hot flush (9,146)
Death (8,772)
Intercepted product preparation error (8,621)
Syringe issue (7,847)
Device leakage (5,861)
Wrong technique in product usage process (5,062)
Fatigue (4,805)
Injection site pain (4,678)
Prostatic specific antigen increased (2,432)
Asthenia (2,176)
What Other Drugs Cause Hormone-refractory prostate cancer?
RADIUM RA-223 DICHLORIDE (441)
DOCETAXEL (123)
ENZALUTAMIDE (120)
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (110)
DAROLUTAMIDE (104)
ABIRATERONE (83)
PREDNISONE (58)
CABAZITAXEL (57)
BICALUTAMIDE (50)
CARBOPLATIN (27)
Which LEUPROLIDE Alternatives Have Lower Hormone-refractory prostate cancer Risk?
LEUPROLIDE vs LEVALBUTEROL
LEUPROLIDE vs LEVAMISOLE
LEUPROLIDE vs LEVAQUIN
LEUPROLIDE vs LEVEMIR
LEUPROLIDE vs LEVETIRACETAM